https://journals.internationalrasd.org/index.php/JOPS/issue/feed iRASD Journal of Pharmaceutical Sciences 2022-01-04T03:28:33-05:00 Prof. Dr. Qaiser Jabeen editor.jops@internationalrasd.org Open Journal Systems <p><em>i</em>RASD Journal of Pharmaceutical Sciences (JOPS) is an international, open access, bi-annual, double-blind, peer-reviewed medical journal in the field of pharmaceutical sciences, which is published under the umbrella of International Research Association for Sustainable Development (<em>i</em>RASD).</p> <p><em>i</em>RASD JOPS is a broad spectrum platform which aims to enlighten the innovative research and bridge-up the gap between research and medical profession. <em>i</em>RASD JOPS publishes high quality original/ hypothesis-driven research articles in pharmaceutics, physical pharmacy, nanotechnology, biopharmaceutics, pharmacology, clinical pharmacology, toxicology, medicinal chemistry, pharmaceutical analysis, pharmacogenomics, pharmacogenetics, pharmacognosy, pharmaceutical microbiology, pharmaceutical biochemistry, and other related disciplines.</p> https://journals.internationalrasd.org/index.php/JOPS/article/view/545 Medicinal Plants of Cholistan Desert for the Management of Inflammatory Disorders: A Review 2022-01-04T03:28:33-05:00 Faraza Javaid farazajaved@gmail.com Hafiz Muhammad Farhan Rasheed h.m.farhan_rasheed@hotmail.com <p><strong>Introduction:</strong> As Cholistan is located in the desert area of Pakistan, there is less availability of allopathic medicines and also a limited number of healthcare providers even for conditions like inflammatory diseases. Local people of Cholistan use plant-based medicines for the management of inflammatory diseases.<br /><strong>Objectives of the study:</strong> This literature survey was carried out to highlight the potential of plant-based medicines used in the management of inflammation and related disorders in the Cholistan region of Pakistan.<br />Material and Methods: Literature from electronic databases such as Google Scholar, Pubmed, and Scopus, and publications from 1986 up to 2020 on medicinal plants of Cholistan desert used to treat inflammation and related disorders, were searched to compile all the relevant data.<br /><strong>Results:</strong> There are 152 plants indigenous to Cholistan desert, which belong to 38 families and are mainly used by the local healers for inflammatory conditions. The anti-inflammatory potential of 152 plants was reviewed; out of which the use of 83 plants, in this review, is backed by in-vivo and in-vitro experimental studies. Roots, barks, tubers, leaves and fruits are important parts while whole plants are also used. The variation in the effects could be due to the difference in the amount of active ingredients in the mixtures and the amount ingested by the patients.<br /><strong>Conclusion:</strong> This review provides help to recognize plant species and assessment of the plant profile used as remedy to treat inflammatory conditions traditionally in Cholistan desert region of Pakistan. These proven benefits of medications extracted from plants are widely used in conventional prescriptions which are less expensive and easily available in healthcare system. A lot of beneficial specifications are compared with the standard pharmacopoeial monographs to assure the reproducibility of their helpful impact. We are confident that the capability of these restorative plants is best fitted towards a potential reconciliation into the medical care network.</p> 2021-12-29T00:00:00-05:00 Copyright (c) 2021 Faraza Javaid, Hafiz Muhammad Farhan Rasheed https://journals.internationalrasd.org/index.php/JOPS/article/view/544 Probable factors impacting the real-world treatment outcomes of direct-acting antivirals for hepatitis C treated populations: A themed review 2022-01-04T03:24:26-05:00 Imran Shahid iyshahid@uqu.edu.sa <p>The therapeutics landscape of hepatitis C is changing expeditiously because of the inclusion of interferon-free antiviral regimens in the treatment strategies. Now, we have highly effective, safe and well-tolerated drugs to cure most patients while achieving higher sustained virologic response rates (SVRs: HCV RNA is undetectable in the serum after the 12 or more weeks of therapy) and hepatitis C recurrence will largely disappear. Such therapeutic regimens in combination or as co-formulated pills present highly efficient treatment options to overcome the hepatitis C related challenges with wide genotype (GT) coverage, short period of treatment and fewer side effects. Interferon-free direct-acting antivirals (IFN-free DAAs) are the drug of choice to triumph the health care burden of hepatitis C infection all over the world, but some challenges still must be met. The therapy costs, treatment access to low and middle-income countries (LMICs), differential routes of hepatitis C transmission and the emergence of treatment-associated adverse events are posing dilemmas too in the real-world clinical experiences. The availability of pan-genotypic DAAs to treat all HCV genotypes/subtypes infections, difficult-to-cure HCV populations and for previous treatment failure with first or second-generation DAAs have made it possible to treat everyone who needs treatment in this decade. The dosage algorithms of certain DAAs are also being evaluated in clinical trials for their administration in infants, children, women of reproductive age and pregnant females. The proposition of this pragmatic review article overviews the treatment based outcomes of these regimens in current clinical settings and highlights the challenges to overcome while achieving the prime objective of hepatitis C elimination by 2030.</p> 2021-12-31T00:00:00-05:00 Copyright (c) 2022 Imran Shahid